How are CYP2C19 and sleep related?

CYP2C19 is a phase I drug-metabolizing enzyme primarily involved in the breakdown of medications such as clopidogrel, proton pump inhibitors, and certain antidepressants (e.g., citalopram, sertraline). A direct, independent link between CYP2C19 variants and sleep quality is not well established. Indirectly, genetic differences in drug metabolism can affect sleep architecture: poor metabolizers experience higher drug levels, which may enhance sedative effects or cause insomnia as a side effect. CYP2C19 also contributes to the metabolism of some benzodiazepines and Z‑drugs. While some studies suggest associations with sleep disturbances, the evidence is largely mechanistic and insufficient for clinical recommendations. Without specific medication use, a direct impact on sleep is unlikely. Consumer DNA tests have limited utility here; persistent sleep issues should be evaluated by a physician.